Avi Abraham Barak
Director/Board Member chez A-ONLINE CAPITAL (A.O.C) LTD.
Profil
Avi Abraham Barak currently works at A-Online Capital (A.O.C.) Ltd., as External Director from 2015, Darban Investments Ltd., as Independent Director from 2012, and BUFF Technologies Ltd., as Independent External Director from 2021.
Mr. Barak also formerly worked at Yissum Research Development Co. Ltd., as President & Chief Executive Officer, BioCancell Therapeutics, Inc., as Chief Executive Officer, Kardan Investments Ltd., as Chairman, Managing Director & Business Manager, and Mizrahi Tefahot Bank Ltd., as Manager-Mutual Funds Division.
Postes actifs de Avi Abraham Barak
| Sociétés | Poste | Début |
|---|---|---|
| A-ONLINE CAPITAL (A.O.C) LTD. | Director/Board Member | 24/12/2015 |
| BUFF TECHNOLOGIES LTD. | Director/Board Member | 14/07/2021 |
Darban Investments Ltd.
 Darban Investments Ltd. Financial ConglomeratesFinance Darban Investments Ltd. engages in the acquisition, construction, and management of office, industrial, commercial, and logistics buildings for rent. The company was founded on August 25, 1986 and is headquartered in Tel Aviv, Israel. | Director/Board Member | 13/03/2012 |
Anciens postes connus de Avi Abraham Barak
| Sociétés | Poste | Fin |
|---|---|---|
BioCancell Therapeutics, Inc.
 BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | President | 30/01/2010 |
| MIZRAHI TEFAHOT BANK LTD. | Corporate Officer/Principal | - |
| Kardan Investments Ltd. | Chairman | - |
Yissum Research Development Co. Ltd.
 Yissum Research Development Co. Ltd. Investment ManagersFinance Yissum Research Development Co. Ltd. (Yissum Research) is a venture capital subsidiary of The Hebrew University of Jerusalem founded in 1964. The firm is headquartered in Jerusalem, Israel. | President | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MIZRAHI TEFAHOT BANK LTD. | Finance |
| BUFF TECHNOLOGIES LTD. | Technology Services |
| Entreprise privées | 5 |
|---|---|
A-Online Capital (A.O.C.) Ltd.
 A-Online Capital (A.O.C.) Ltd. Packaged SoftwareTechnology Services A-Online Capital Ltd. engages in the development and marketing of software for the capital market. Its products include e-Signal, Megama, Ticker, Ace, and iBursa for iPhone. The company was founded in 2003 and is headquartered in Tel Aviv, Israel. | Technology Services |
Yissum Research Development Co. Ltd.
Yissum Research Development Co. Ltd. Investment ManagersFinance Yissum Research Development Co. Ltd. (Yissum Research) is a venture capital subsidiary of The Hebrew University of Jerusalem founded in 1964. The firm is headquartered in Jerusalem, Israel. | Finance |
| Kardan Investments Ltd. | Finance |
Darban Investments Ltd.
Darban Investments Ltd. Financial ConglomeratesFinance Darban Investments Ltd. engages in the acquisition, construction, and management of office, industrial, commercial, and logistics buildings for rent. The company was founded on August 25, 1986 and is headquartered in Tel Aviv, Israel. | Finance |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | Health Technology |
